Iridex Q4 2023 GAAP EPS $(0.18) Misses $(0.05) Estimate, Sales $12.458M Miss $14.900M Estimate

3/26/24 4:27:05 PM ET

Biotechnology: Electromedical & Electrotherapeutic Apparatus

Health Care

Get the next $IRIX alert in real time by email

Iridex (NASDAQ:IRIX) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $(0.05) by 260 percent. The company reported quarterly sales of $12.458 million which missed the analyst consensus estimate of $14.900 million by 16.39 percent. This is a 18.01 percent decrease over sales of $15.195 million the same period last year.

Get the next $IRIX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$IRIX

Date	Price Target	Rating	Analyst

More analyst ratings

$IRIX
Press Releases

Fastest customizable press release news feed in the world

Iridex Comments on Changing Glaucoma Reimbursement Landscape
MOUNTAIN VIEW, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today confirms that Local Coverage Determination (LCD) L37531, relating to Micro-Invasive Glaucoma Surgery (MIGS), was adopted as scheduled and will be effective for services performed on or after November 17, 2024. The Company has previously reported that it believes the reimbursement limitations created by the new LCD has potential to significantly increase physician interest in and use of Iridex's advanced laser-based treatmen
11/19/24 8:14:07 AM ET
$IRIX
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Iridex Reports Third Quarter 2024 Financial Results
MOUNTAIN VIEW, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the third quarter ended September 28, 2024. Third Quarter 2024 Financial and Recent Highlights Expects to achieve EBITDA breakeven in the fourth quarter of 2024 as a result of actions to reduce costs and improve profitabilityGenerated total revenue of $11.6 million, representing a decline of 8% sequentially from the second quarter of 2024 and a decline of 10% over Q3'23Cyclo G6® product fami
11/12/24 4:05:00 PM ET
$IRIX
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Iridex to Report Third Quarter 2024 Financial Results on November 12, 2024
MOUNTAIN VIEW, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the third quarter 2024 and provide a business update after the close of trading on Tuesday, November 12, 2024. The Company's management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing 1-888-596-4144 for domestic callers or +1-646-968-2525 for interna
11/4/24 4:05:00 PM ET
$IRIX
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care

Iridex Appoints Patrick Mercer as Chief Executive Officer
MOUNTAIN VIEW, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the appointment of Patrick Mercer as the Company's Chief Executive Officer and President effective October 1, 2024. Previously Mr. Mercer served as the Company's Chief Operating Officer and President. David Bruce, the Company's prior Chief Executive Officer, is transitioning from the Company. Coincident to Mr. Mercer's appointment, Scott Shuda was appointed Executive Chairman of the Company's board of directors. M
10/3/24 4:05:00 PM ET
$IRIX
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Iridex Announces First Patient Enrollment in MicroPulse® TLT Clinical Study Conducted in Collaboration with Imperial College Healthcare NHS Trust
MOUNTAIN VIEW, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation, headquartered in Mountain View, California, and Imperial College Healthcare NHS Trust in London, today announced the first patient enrollment in a collaborative medical research study and registry evaluating the treatment of glaucoma with MicroPulse® Transscleral Laser Therapy (TLT) using Iridex' Cyclo G6® Laser and the MicroPulse P3® Delivery Device. This partnership establishes a large-scale enrollment platform to advance clinical research. David I. Bruce, President and CEO of Iridex, shared: "The first patient enrollment in this partnership with Imperial College Healthcare NHS Trust is the first step toward mu
1/24/24 8:00:00 AM ET
$IRIX
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Iridex Announces the Appointment of Beverly Huss to its Board of Directors
MOUNTAIN VIEW, Calif., March 21, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the appointment of Beverly Huss to its board of directors, effective, March 17, 2022. In connection with Ms. Huss' appointment to the board, the size of the board was increased from five to six members as of the Effective Date. "I am very pleased to welcome Beverly to our board of directors," said Scott Shuda, chairman of the board of Iridex. "Beverly's extensive management and board experience in the medical device industry and proven track record with non-invasive a
3/21/22 4:05:00 PM ET
$IRIX
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care

$IRIX
Financials

Live finance-specific insights

Iridex Reports Third Quarter 2024 Financial Results
MOUNTAIN VIEW, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the third quarter ended September 28, 2024. Third Quarter 2024 Financial and Recent Highlights Expects to achieve EBITDA breakeven in the fourth quarter of 2024 as a result of actions to reduce costs and improve profitabilityGenerated total revenue of $11.6 million, representing a decline of 8% sequentially from the second quarter of 2024 and a decline of 10% over Q3'23Cyclo G6® product fami
11/12/24 4:05:00 PM ET
$IRIX
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Iridex to Report Third Quarter 2024 Financial Results on November 12, 2024
MOUNTAIN VIEW, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the third quarter 2024 and provide a business update after the close of trading on Tuesday, November 12, 2024. The Company's management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing 1-888-596-4144 for domestic callers or +1-646-968-2525 for interna
11/4/24 4:05:00 PM ET
$IRIX
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Iridex Reports Second Quarter 2024 Financial Results
MOUNTAIN VIEW, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the second quarter ended June 29, 2024, and provided a business update. Second Quarter 2024 Financial and Recent Highlights Generated total revenue of $12.6 million, representing sequential growth of 7% from the first quarter of 2024Cyclo G6® product family revenue was $3.3 million, representing sequential growth of 13% from the first quarter of 2024 Sold 15,100 Cyclo G6 probes, compared to
8/8/24 4:05:00 PM ET
$IRIX
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care

Iridex Q4 2023 GAAP EPS $(0.18) Misses $(0.05) Estimate, Sales $12.458M Miss $14.900M Estimate

Chat with this insight

Recent Analyst Ratings for $IRIX

$IRIX Press Releases

Fastest customizable press release news feed in the world

Iridex Comments on Changing Glaucoma Reimbursement Landscape

Iridex Reports Third Quarter 2024 Financial Results

Iridex to Report Third Quarter 2024 Financial Results on November 12, 2024

$IRIX SEC Filings

IRIDEX Corporation filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

SEC Form 10-Q filed by IRIDEX Corporation

IRIDEX Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$IRIX Market Insights

Live Market Insights

Stifel Maintains Hold on Iridex, Maintains $2 Price Target

IRIDEX shares are trading lower after the company reported worse-than-expected Q1 financial results.

IRIDEX shares are trading lower after the company reported worse-than-expected Q1 financial results.

$IRIX Leadership Updates

Live Leadership Updates

Iridex Appoints Patrick Mercer as Chief Executive Officer

Iridex Announces First Patient Enrollment in MicroPulse® TLT Clinical Study Conducted in Collaboration with Imperial College Healthcare NHS Trust

Iridex Announces the Appointment of Beverly Huss to its Board of Directors

$IRIX Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Roth Capital reiterated coverage on Iridex with a new price target

Roth Capital reiterated coverage on IRIDEX with a new price target

Roth Capital reiterated coverage on Iridex with a new price target

$IRIX Financials

Live finance-specific insights

Iridex Reports Third Quarter 2024 Financial Results

Iridex to Report Third Quarter 2024 Financial Results on November 12, 2024

Iridex Reports Second Quarter 2024 Financial Results

$IRIX Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13D filed by IRIDEX Corporation

SEC Form SC 13D filed by IRIDEX Corporation

SEC Form SC 13G/A filed by IRIDEX Corporation (Amendment)

$IRIX Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

President and CEO Mercer Patrick was granted 200,000 shares, increasing direct ownership by 103% to 393,244 units (SEC Form 4)

President and COO Mercer Patrick covered exercise/tax liability with 2,073 shares, decreasing direct ownership by 1% to 193,244 units (SEC Form 4)

CEO Bruce David covered exercise/tax liability with 4,788 shares, decreasing direct ownership by 4% to 126,480 units (SEC Form 4)

Recent Analyst Ratings for
$IRIX

$IRIX
Press Releases

$IRIX
SEC Filings

$IRIX
Market Insights

$IRIX
Leadership Updates

$IRIX
Analyst Ratings

$IRIX
Financials

$IRIX
Large Ownership Changes

$IRIX
Insider Trading